No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in Sanofi rose as the French pharma giant beat first-quarter sales estimates on Thursday on continuing demand for its Dupixent asthma and eczema drug just before the arrival of new chief executive Beln Garijo.
Dupixent sales increased by 30.8% to 4.2 billion. The company reported total sales of 10.51bn for the three months to March 31, up 6.2%. Analysts on average expected sales of 10.22bn. Shares in the company were up 3.3% in Paris.
Quarterly business operating income rose 2.2% to 2.97bn, beating estimates of 2.85bn.
"We reiterate our guidance for 2026: we continue to expect sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, at constant exchange rates, delivering profitable growth. We are also looking forward to welcoming Beln Garijo as the new CEO of Sanofi from next month," said interim boss Olivier Charmeil.
Reporting by Frank Prenesti for Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.